Literature DB >> 12045060

Long-term outcome of keratolimbal allograft with or without penetrating keratoplasty for total limbal stem cell deficiency.

Abraham Solomon1, Pierre Ellies, David F Anderson, Amel Touhami, Martin Grueterich, Edgar M Espana, Seng-Ei Ti, Eiki Goto, William J Feuer, Scheffer C G Tseng.   

Abstract

PURPOSE: To evaluate the long-term outcome of ocular surface reconstruction, including keratolimbal allograft (KLAL) and amniotic membrane transplantation (AMT) with or without penetrating keratoplasty (PKP), in patients with nonambulatory vision secondary to total limbal stem cell deficiency (LSCD).
DESIGN: Retrospective, non-comparative interventional case series. PARTICIPANTS: Thirty-nine eyes in 31 consecutive patients with total LSCD, as defined by impression cytology, who had a preoperative best-corrected visual acuity of less than 20/200 and a minimum follow-up of 12 months. Patients were divided into three groups: group 1 (16 eyes) with chemical burns, group 2 (9 eyes) with Stevens-Johnson syndrome (SJS), and group 3 (14 eyes) with other causes of LSCD, including ocular cicatricial pemphigoid, atopic keratoconjunctivitis, and aniridia. INTERVENTION: All patients underwent KLAL and AMT by one surgeon (SCGT). If needed, PKP was performed at the same surgical setting using tissue from the same donor. MAIN OUTCOME MEASURES: Cumulative rates of survival of ambulatory vision (> or = 20/200), survival of KLAL, survival of PKP, and incidence of complications.
RESULTS: Fifty-three KLAL with AMT procedures were performed in 39 eyes, of which 23 eyes received simultaneous PKP at the time of the first KLAL. The mean follow-up was 34.0 +/- 21.5 months (range, 12-117.6). The mean period of ambulatory vision was 23.9 +/- 20.9 months (range, 0-104). The overall survival of ambulatory vision was 53.6% at 3 years and 44.6% at 5 years. The survival of ambulatory vision was significantly worse in SJS compared with other causes (67%, 81%, and 92% for groups 1, 2, and 3, respectively; P = 0.06 for group 1 versus 2, P = 0.0008 for group 1 versus 3). KLAL performed alone resulted in higher survival of ambulatory vision at 2 years (86.1% +/- 9.1%) compared with KLAL with PKP (46.9% +/- 10.6%, P = 0.100). The survival of PKP was significantly worse in SJS compared with the other causes (20.0% +/- 17.9% compared with 55.6% +/- 11.7%, respectively, P = 0.028). After 2 years, the survival of the second KLAL was better than that of the first: 68.2% +/- 15.4% compared with 27.3% +/- 13.4%, respectively (P = 0.041).
CONCLUSIONS: Ambulatory vision for a period of more than 2 years can be achieved by KLAL with or without PKP in eyes with severe ocular surface disorders caused by total LSCD. However, a progressive decline of the visual outcome and graft survival is evident with time. Performing PKP simultaneously with KLAL may be associated with a less favorable outcome. The failure of KLAL is associated with the loss of donor cells in the recipient. Augmentation of ocular surface defense is essential in securing the success of KLAL and PKP. Future modifications of the surgical procedure and of the immune suppressive protocols may improve survival of the allogeneic grafts and the final visual outcome.

Entities:  

Mesh:

Year:  2002        PMID: 12045060     DOI: 10.1016/s0161-6420(02)00960-0

Source DB:  PubMed          Journal:  Ophthalmology        ISSN: 0161-6420            Impact factor:   12.079


  51 in total

1.  Cost effectiveness of the type II Boston keratoprosthesis.

Authors:  J D Ament; T P Stryjewski; S Pujari; S Siddique; G N Papaliodis; J Chodosh; C H Dohlman
Journal:  Eye (Lond)       Date:  2010-12-24       Impact factor: 3.775

Review 2.  Graft failure: II. Ocular surface complications.

Authors:  Samar A Al-Swailem
Journal:  Int Ophthalmol       Date:  2008-06       Impact factor: 2.031

3.  Medium term results in keratoprostheses with biocompatible and biological haptic.

Authors:  K Hille; A Hille; K W Ruprecht
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2005-11-19       Impact factor: 3.117

4.  Long-term outcome and prognostic factor analysis for keratolimbal allografts.

Authors:  Eui Seok Han; Won Ryang Wee; Jin Hak Lee; Mee Kum Kim
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2011-08-12       Impact factor: 3.117

5.  Plasma polymer-coated contact lenses for the culture and transfer of corneal epithelial cells in the treatment of limbal stem cell deficiency.

Authors:  Karl David Brown; Suet Low; Indumathi Mariappan; Keren Maree Abberton; Robert Short; Hong Zhang; Savitri Maddileti; Virender Sangwan; David Steele; Mark Daniell
Journal:  Tissue Eng Part A       Date:  2014-01-23       Impact factor: 3.845

6.  Functional reconstruction of rabbit corneal epithelium by human limbal cells cultured on amniotic membrane.

Authors:  Yiqin Du; Jing Chen; James L Funderburgh; Xiuan Zhu; Lingsong Li
Journal:  Mol Vis       Date:  2003-12-08       Impact factor: 2.367

Review 7.  Current and emerging therapies for corneal neovascularization.

Authors:  Danial Roshandel; Medi Eslani; Alireza Baradaran-Rafii; Albert Y Cheung; Khaliq Kurji; Sayena Jabbehdari; Alejandra Maiz; Setareh Jalali; Ali R Djalilian; Edward J Holland
Journal:  Ocul Surf       Date:  2018-06-20       Impact factor: 5.033

8.  Comprehensive approach to ocular consequences of Stevens Johnson Syndrome - the aftermath of a systemic condition.

Authors:  Geetha Iyer; Bhaskar Srinivasan; Shweta Agarwal; Seema Kamala Muralidharan; Sumathi Arumugam
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2014-01-29       Impact factor: 3.117

9.  Recent advances in corneal regeneration and possible application of embryonic stem cell-derived corneal epithelial cells.

Authors:  Maki Kayama; Manae S Kurokawa; Hiroki Ueno; Noboru Suzuki
Journal:  Clin Ophthalmol       Date:  2007-12

10.  A serum- and feeder-free technique of culturing human corneal epithelial stem cells on amniotic membrane.

Authors:  Kaevalin Lekhanont; Lulin Choubtum; Roy S Chuck; Tarinee Sa-ngiampornpanit; Varintorn Chuckpaiwong; Anun Vongthongsri
Journal:  Mol Vis       Date:  2009-06-30       Impact factor: 2.367

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.